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Abstract
Background: Human adenovirus serotype 5 (Ad5) has been widely explored as a gene delivery
vector for a variety of diseases. Many target cells, however, express low levels of Ad5 native
receptor, the Coxsackie-Adenovirus Receptor (CAR), and thus are resistant to Ad5 infection. The
Protein Transduction Domain of the HIV Tat protein, namely PTDtat, has been shown to mediate
protein transduction in a wide range of cells. We hypothesize that re-targeting Ad5 vector via the
PTDtat motif would improve the efficacy of Ad5-mediated gene delivery.
Results: In this study, we genetically incorporated the PTDtat motif into the knob domain of Ad5
fiber, and rescued the resultant viral vector, Ad5.PTDtat. Our data showed the modification did not
interfere with Ad5 binding to its native receptor CAR, suggesting Ad5 infection via the CAR
pathway is retained. In addition, we found that Ad5.PTDtat exhibited enhanced gene transfer efficacy
in all of the cell lines that we have tested, which included both low-CAR and high-CAR decorated
cells. Competitive inhibition assays suggested the enhanced infectivity of Ad5.PTDtat was mediated
by binding of the positively charged PTDtat peptide to the negatively charged epitopes on the cells'
surface. Furthermore, we investigated in vivo gene delivery efficacy of Ad5.PTDtat  using
subcutaneous tumor models established with U118MG glioma cells, and found that Ad5.PTDtat
exhibited enhanced gene transfer efficacy compared to unmodified Ad5 vector as analyzed by a
non-invasive fluorescence imaging technique.
Conclusion: Genetic incorporation of the PTDtat motif into Ad5 fiber allowed Ad5 vectors to
infect cells via an alternative PTDtat targeting motif while retaining the native CAR-mediated
infection pathway. The enhanced infectivity was demonstrated in both cultured cells and in in vivo
tumor models. Taken together, our study identifies a novel tropism expanded Ad5 vector that may
be useful for clinical gene therapy applications.
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Background
Human adenovirus serotype 5 (Ad5) has been widely
exploited as a gene delivery vector, owing largely to its
superior gene delivery efficacy, minor pathological effect
on humans, and easy manipulation in vitro. Several prob-
lems, however, have been identified in the course of
development and application of Ad5-based gene therapy
protocols, one of which is the inefficient gene delivery
into target cells [1-3]. It is known that infection of Ad5 is
initiated by attachment of its capsid fiber protein to the
cell surface coxsackievirus adenovirus receptor (CAR),
which is followed by interaction of its penton base with αv
integrins that triggers the internalization of the viruses [4-
7]. Many target cells, such as malignant tumor cells, are
found to express very low level of CAR, and thus are resist-
ant to Ad5 infection. Therefore, strategies to re-direct Ad5
infection via alternative receptors would be useful for
gene therapy applications.
Since fiber, the capsid protein extruding from the Ad vir-
ion surface, is an essential mediator of Ad5 infection, fiber
modification has been explored as a means to re-direct
Ad5 tropism [1]. Ad5 fiber is composed of an N-terminal
tail that is attached to a penton base on the virion surface,
a shaft domain consisting of 22 repeats of a 15-amino acid
residue motif, and a C-terminal globular domain, named
knob, which functions as a receptor binding domain.
Because of the essential role of the fiber knob domain in
mediating Ad5 infection, knob modification could be one
of the most effective ways to re-direct Ad5 tropism.
Indeed, both genetic and non-genetic strategies have been
shown to successfully retarget Ad5 vectors. For example,
bi-specific adapter proteins that bind both the knob
domain and an alternative receptor expressed on the sur-
face of the target cells have been employed to re-direct
Ad5 infection [8-11]. In addition, genetic incorporation
of RGD peptide and/or a polylysine epitope into the knob
domain allowed Ad5 to infect cells through alternative
receptors (cell surface integrins for RGD and negatively
charged epitopes such as heparan sulfate proteoglycans
for polylysine), thus greatly improving the gene delivery
efficacy Ad5 vectors in many target cells [12-15].
Protein transduction domains (PTD) or Cell Penetrating
Peptides (CPP) are a class of small peptides that can
traverse the plasma membrane of many, if not all, mam-
malian cells [16-20]. Among these peptides, the PTD of
the Tat protein (PTDtat) of human immunodeficiency
viruses types 1 and 2 (HIV-1 and HIV-2) has been one of
the most widely studied PTDs. PTDtat consists of 11 highly
basic amino acid residues, YGRKKRRQRRR [21,22]. The
mechanism of how PTDtat crosses the cell membrane has
been intensively studied, but controversies remain [23-
26]. Nonetheless, it is commonly agreed upon that the
interaction between the positive charge of the PTD
domain and the negative epitopes, in particular, the
heparan sulfate proteoglycans expressed on cell mem-
branes, plays an essential role in the internalization of
PTDtat fusion proteins [17,20,27]. Further studies suggest
that the interaction between PTDtat and heparan sulfate is
specified by both charge and structure of the peptide and
the proteoglycans [17,27-30].
Given the potential importance of the PTDs in drug deliv-
ery, much interest has been generated in exploiting this
system as a tool to deliver therapeutic molecules or parti-
cles into mammalian cells. PTDs have already been widely
used in the field of protein therapy whereby PTDs are
fused to the protein of interest, and used to deliver the het-
erologous protein into cultured cells [17,20,31]. Interest-
ingly, it has been demonstrated in several mouse studies
that PTDtat fusion proteins can be delivered into different
tissues  in vivo following systemic administration, and
therapeutic benefits have been observed [32-35]. In addi-
tion, PTDs have been used to deliver other large molecules
or particles including plasmids, liposomes, nanoparticles,
phages and viruses, with variable efficiency [36-41]. In
these applications, PTDs were conjugated to the vehicle of
interest by incubation in coupling solutions. In other
words, the coating of the vehicle was not based on genetic
modification, but on ionic or other interactions between
the peptides and the vehicle.
Because of the potency of PTDtat in mediating cellular
uptake of small and large molecules, in this study, we
attempted to re-direct Ad5 infection via the PTDtat path-
way. Previous studies have demonstrated pre-treatment of
Ad particles with chemically synthesized PTDs or bi-spe-
cific adaptor proteins composed of the extracellular
domain of CAR and PTDs improved Ad infection [37,42].
Nonetheless, intrinsic to these non-genetic modification
strategies, the efficiency of retargeting depended on the
affinity and stability of protein-protein interactions, and
thus may be highly variable in different systems. In addi-
tion, a large amount of peptide or adaptor protein is seen
to be required for in vivo investigations. Our study was
designed to retarget Ad5 vectors to the PTDtat pathway
using a genetic capsid modification strategy. We geneti-
cally incorporated the sequences encoding the PTDtat pep-
tide into the 3' end of the Ad5 fiber gene, rescued the
modified viruses, and characterized them in detail. Our
data demonstrated that genetic modification of Ad5 fiber
with the PTDtat motif greatly improved the efficacy of gene
delivery in both cultured cells and in tumor models. Our
study thus identified a novel tropism expanded Ad5 vec-
tor that may be useful for clinical gene therapy applica-
tions, especially for applications involving gene delivery
into low-CAR expressing cells.Virology Journal 2007, 4:103 http://www.virologyj.com/content/4/1/103
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Results
Development of PTDtat-modified Ad5 vector – Ad5.PTDtat
As the receptor binding domain, the knob of the Ad5 fiber
has been shown to be an effective site for incorporating
foreign targeting motifs [12-15]. In this study, we geneti-
cally incorporated the PTDtat epitope into the C-terminal
end of the fiber knob domain (Fig. 1). The Ad5 genome
contains about 36 kilobases (kb) and is too large for direct
modification using conventional cloning techniques. To
achieve our goal, we therefore established a bacteria-based
homologous recombination system for Ad5 fiber modifi-
cation [15]. Using this system, the nucleotide sequences
encoding PTDtat were incorporated into the 3'end of the
fiber gene, immediately before the stop code. The modi-
fied Ad5 (Ad5.PTDtat) and the unmodified control (Ad5)
were both replication deficient as their E1 region, which is
essential for Ad5 replication, was replaced with a CMV
promoter-driven green fluorescence protein (GFP)
reporter gene. The viruses were rescued in 293 cells stably
expressing Ad-E1 genes, and purified with CsCl gradient
ultracentrifugation. The yield of Ad5.PTDtat total viral par-
ticles (VPs) and the ratio of VPs : plaque formation units
(pfu) were in the same range as that of unmodified Ad5
viruses, suggesting that the modification did not interfere
with virus formation (data not shown). The modification
was confirmed by both polymerase chain reaction (PCR)
and sequence analysis of the modified region of the viral
genome using viral DNA from purified Ad5 and Ad5.PTD-
tat viruses (data not shown).
CAR-binding activity of Ad5.PTDtat
Unmodified Ad5 viruses interact with their native receptor
CAR via the fiber knob domain. We thus examined
whether incorporation of PTDtat into the knob domain
interfered with the Ad5-CAR interaction. An enzyme-
linked immunosorbent assay (ELISA) was employed in
this regard. In the assay, Ad5.PTDtat or Ad5 viral particles
were immobilized in the wells of a 96-well maxi-sorp
plate, and incubated with varying amounts of recom-
binant extracellular domain of CAR (sCAR) protein. After
extensive washing, binding of sCAR to the viruses were
assessed with an anti-CAR antibody and corresponding
secondary antibody conjugated to alkaline phosphatase
(AP). The OD405 readings resulting from the color reac-
tion with an AP substrate correspond to the binding activ-
ity of sCAR to the viruses. As shown in Fig. 2, binding of
sCAR to Ad5.PTDtat is similar to that of unmodified Ad5,
suggesting the genetically modified vector Ad5.PTDtat
maintained its ability to interact with the Ad5 native
receptor, CAR.
Cell-binding activities of Ad5.PTDtat
The fiber knob domain of Ad is responsible for Ad5 bind-
ing to its target cells, which is the initial step in viral infec-
tion. Ad5.PTDtat was designed to re-direct Ad5 infection.
Ad5.PTDtat showed similar CAR-binding activity to unmodi- fied Ad5 vector in an ELISA-based binding assay Figure 2
Ad5.PTDtat showed similar CAR-binding activity to 
unmodified Ad5 vector in an ELISA-based binding 
assay. In the experiment, 109 VPs of each viral vector were 
immobilized in the wells of a 96-well ELISA plate, and incu-
bated with increasing concentrations of recombinant sCAR 
(extracellular domain of CAR, i.e. soluble CAR). The binding 
activity was detected by AP activity conjugated to detection 
antibodies.
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Diagram of PTDtat modified Ad5 vector Figure 1
Diagram of PTDtat modified Ad5 vector. (A) PTDtat 
peptide incorporated into the fiber knob domain. (B) Struc-
tural diagram of Ad5 and Ad5.PTDtat vector. The PTDtat 
motif was incorporated at the C-terminal end of the fiber.
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We thus examined whether PTDtat modification had any
effect on Ad5 binding to cells. To distinguish viruses
bound to cells from viruses internalized into the cells, we
performed a cell binding assay at 4°C since Ad internali-
zation occurs through receptor-mediated endocytosis
which is energy dependent, and is thus inhibited at 4°C
[5,7]. In the assay, Ad5.PTDtat or control Ad5 was incu-
bated with cells expressing different levels of CAR at 4°C
for 1 hour, and the bound viral particles were examined
by a quantitative PCR assay which assessed the viral
genome copies in the cell lysates. We found that Ad5.PTD-
tat exhibited a significant higher cell-binding activity in
almost all of the cells we examined, including both high-
CAR and low-CAR containing cells. Shown in Fig. 3 are
results obtained in two representative cell lines: high-CAR
expressing Hela cells, and low-CAR expressing U118MG
cells [43,44].
Enhanced gene transfer efficacy of Ad5.PTDtat
We further investigated the gene transfer efficacy of
Ad5.PTDtat in a variety of cultured cells using the reporter
GFP protein. Ad5.PTDtat vector or unmodified Ad5 was
used to infect cells at different multiplicities of infection
(MOIs). Two days after infection, we evaluated the trans-
gene expression using a fluorescent microscope and a flu-
orescent plate reader. We found that Ad5.PTDtat showed
more efficient gene delivery than unmodified Ad5 in all of
the cells tested (Fig. 4). In particular, Ad5.PTDtat exhibited
significantly higher gene transfer efficacy than unmodi-
fied Ad5 in the cells expressing low or medium levels of
CAR such as RD cells, U118MG cells, and D65MG cells
[43,44]. In high-CAR expressing cells that are readily
accessible to unmodified Ad5 vector, Ad5.PTDtat  also
showed enhanced infectivity, presumably because
Ad5.PTDtat maintained the CAR-mediated infection path-
way while gaining extra targeting activity through the
PTDtat pathway (Fig. 4).
Identification of pathways mediating Ad5.PTDtat infection
Ad5.PTDtat showed enhanced gene delivery efficacy com-
pared to unmodified Ad5 vectors. To confirm that this
expanded tropism was mediated by the genetically incor-
porated targeting motif PTDtat, we performed a gene trans-
fer assay in the presence of competitive inhibitors. It has
been shown that the interaction between the positively
charged PTDtat and the negatively charged cell surface
epitopes such as heparan sulfate proteoglycans is essential
for PTDtat mediated protein transduction. Heparin, the
structural analogue of heparan sulfate, would thus be
expected to inhibit PTDtat mediated infection. In addition,
recombinant knob protein was used to block the native
CAR-mediated Ad5 infection because it compete with Ad5
vectors for cell surface CAR. In low-CAR containing
U118MG cells [44], due to the paucity of CAR, unmodi-
fied Ad5 showed poor gene transfer efficacy, and neither
knob nor heparin had any effect on Ad5-mediated trans-
gene expression (Fig. 5A). In contrast, Ad5.PTDtat exhib-
ited efficient gene delivery into U118MG cells, which was
completely inhibited by heparin, but not by the recom-
binant knob protein (Fig. 5A). These data demonstrated
PTDtat modification promoted Ad5 binding to cell surfaces Figure 3
PTDtat modification promoted Ad5 binding to cell 
surfaces. Binding of Ad5 and Ad5.PTDtat were examined in 
both high-CAR expressing Hela cells (A) and low-CAR 
expressing U118MG cells (B) at 4°C. The amount of viruses 
associated with the cells was determined by quantitative PCR 
after DNA isolation from the cell lysate, and the viral copy 
numbers were normalized to actin DNA in the samples. The 
* indicates p < 0.05 and ** indicates p < 0.01 as analyzed by 
the Student's t-test.
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Ad5.PTDtat exhibited enhanced gene transfer efficacy in a variety of tumor cells Figure 4
Ad5.PTDtat exhibited enhanced gene transfer efficacy in a variety of tumor cells. Gene transfer efficacy was evalu-
ated by use of a GFP reporter that was carried in the E1 region of each vector. In the assay, tumor cells expressing varying lev-
els of CAR were infected with either Ad5 or Ad5.PTDtat at an MOI of 100 or 500 VPs/cell, and GFP expression was examined 
by fluorescence microscopy and a fluorescence plate reader. (A) Representative fluorescence images of low-CAR containing 
cells (RD), medium-CAR containing cells (D65MG) and high-CAR expressing cells (Hela) that were infected with Ad5 or 
Ad5.PTDtat at an MOI of 500 VPs/cell. (B) GFP expression in a variety of cells infected with either Ad5 or Ad5.PTDtat was quan-
tified using a fluorescence plate reader.
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Ad5.PTDtat  infected low-CAR expressing cells mainly
through the incorporated PTDtat motif. In high-CAR con-
taining A549 cells [43], infection of unmodified Ad5 was
completely blocked by recombinant knob protein while
heparin had little effect, confirming that unmodified Ad5
mainly infected cells through the CAR pathway (Fig. 5B).
On the other hand, Ad5.PTDtat-mediated gene transfer
was partially blocked by either knob or heparin, but com-
pletely blocked in the presence of both knob and heparin,
suggesting Ad5.PTDtat could infect cells via both CAR and
the PTDtat motif (Fig. 5B).
In vivo gene transfer efficacy of Ad5.PTDtat
We next examined whether the infectivity-enhanced vec-
tor Ad5.PTDtat could deliver enhanced gene transfer effi-
cacy  in vivo. Since Ad5.PTDtat showed more profound
infectivity enhancement for low-CAR expressing tumor
cells in vitro, we assessed the in vivo gene delivery efficacy
of the Ad5 vectors using tumor models established with
low-CAR containing U118MG cells. After the tumors were
established subcutaneously in athymic (nude) mice, PBS,
unmodified Ad5, or Ad5.PTDtat vectors were injected into
the tumors. The gene delivery efficacy of each vector was
analyzed by non-invasive fluorescence imaging that
detected GFP expression in live mice. As shown in Fig. 6A,
Competitive inhibition assay showing the enhanced gene transfer efficacy of Ad5 Figure 5
Competitive inhibition assay showing the enhanced gene transfer efficacy of Ad5.PTDtat was mediated by the 
PTDtat motif. In this assay, recombinant knob protein (50 µg/ml) was used to block CAR-mediated viral infection, and heparin 
(100 µg/ml) was used to block PTDtat mediated infection. Infections were performed at an MOI of 100 VPs/cell. (A) In low-
CAR expressing U118MG cells that were resistant to unmodified Ad5 vector, Ad5.PTDtat mediated efficient gene delivery and 
the efficacy was completely inhibited by heparin, while recombinant knob had little effect, suggesting the enhanced infectivity of 
Ad5.PTDtat in low-CAR expressing cells resulted from the PTDtat motif. (B) In high-CAR expressing A549 cells, Ad5.PTDtat 
mediated gene delivery was partially inhibited with either knob or heparin, while being completely inhibited in the presence of 
both inhibitors, suggesting Ad5.PTDtat infected high-CAR expressing cells via both CAR and PTDtat pathways.Virology Journal 2007, 4:103 http://www.virologyj.com/content/4/1/103
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Ad5.PTDtat-infected tumors showed more intensive green
fluorescence signals than Ad5-infected tumors, while no
signal was detected in PBS-injected tumors. Quantitative
analysis of the green fluorescence signals revealed that
Ad5.PTDtat-mediated GFP expression was significantly
higher than that of unmodified Ad5 vector in the tumors
(p < 0.01) (Fig. 6B). These data suggest the infectivity-
enhanced Ad5.PTDtat vector could be a useful vector for in
vivo gene delivery into tumors, which is essential for can-
cer gene therapy.
Discussion
In this study, we sought to improve the gene transfer effi-
cacy of Ad 5 vectors by genetic modification of the fiber
knob domain with a PTDtat motif. Our data demonstrated
the success of this strategy. The fiber modified Ad5 vector,
Ad5.PTDtat, not only exhibited enhanced gene delivery
efficiency of Ad5 vectors in low-CAR cells that are resistant
to unmodified Ad5 infection, but also in high-CAR cells
that are permissive to Ad5 infection. The enhanced infec-
tivity of Ad5.PTDtat was found to be mediated by targeting
of PTDtat  to the negatively charged epitopes such as
heparan sulfate containing proteoglycans on cell surface.
In addition, we found PTDtat mediated Ad5.PTDtat infec-
tion is additive to native CAR-mediated infection as
assessed by competitive inhibition assays, which was not
unexpected since Ad5.PTDtat maintained full CAR-bind-
ing activity. More significantly, the enhanced gene deliv-
ery efficacy of Ad5.PTDtat was demonstrated in vivo using
low-CAR U118MG tumor models, and employment of a
recently developed non-invasive optical imaging system
PTDtat modification of Ad5 fiber enhanced in vivo gene delivery efficacy of the vector Figure 6
PTDtat modification of Ad5 fiber enhanced in vivo gene delivery efficacy of the vector. In vivo gene delivery of 
Ad5.PTDtat was examined using a non-invasive fluorescence imaging technique in low-CAR expressing tumor models. 1010 VPs 
of Ad5 or Ad5.PTDtat were injected into the subcutaneous U118MG tumors, and in vivo green fluorescence images were 
acquired at different days post viral injection. (A) Representative in vivo images from PBS, Ad5, or Ad5.PTDtat injected mouse 
tumor models at day 7 after vector administration. The colors representing different intensities of signal are shown on the 
color bar. Ad5.PTDtat infection resulted in more intensive GFP signals than unmodified Ad5 vectors. (B) Quantitative analysis of 
the GFP intensity in the tumor model of each group. The * marks significant differences (p < 0.01) as analyzed by the Student's 
t-test.
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allowed us to visually detect the enhanced gene delivery in
vivo.
As a cell penetrating peptide, PTDtat is capable of travers-
ing the plasma membrane of mammalian cells. Since the
initial description that PTDtat is responsible for the ability
of the HIV Tat protein to enter mammalian cells, PTDtat
has attracted tremendous interest as a drug delivery vehi-
cle [16-20]. Further interest has been stimulated by the
observation that PTDs can facilitate systemic delivery of
biologically active recombinant proteins in vivo [32-
35,37]. Since inefficient gene delivery into target cells has
been one of the major limitations in Ad5-mediated gene
therapy, in this study, we attempted to employ PTDtat pep-
tide to facilitate Ad5 mediated gene delivery. Employment
of PTDs to facilitate virus infection has been investigated
previously, but only using non-genetic methods [37,42].
In particular, chemically synthesized PTDs or bi-specific
adaptor proteins consisting of PTDs and the extracelluar
domain of CAR have been used to coat Ad vectors. These
strategies too resulted in enhanced gene delivery [37,42].
Compared to the non-genetic methods, our genetically
PTDtat  modified vector has major advantages for two
major reasons: 1) genetic modification allows stable inter-
action between Ad5 and the PTDtat targeting epitope, thus
reducing the volatility associated with the affinity and sta-
bility of protein-protein interactions in the presence of
different environmental factors. This is critical especially
for in vivo applications; and 2) genetic modification does
not require production of peptides or fusion proteins
other than the viral vector, while large amounts of high
quality protein/peptide production is required for non-
genetic strategies (in addition to high quality production
of the viral vectors), which is especially important for in
vivo studies.
One issue associated with PTDtat-mediated protein deliv-
ery is the inefficient release of PTDtat fusion proteins from
the endosomal compartments [24,45-48]. It has been
demonstrated that a large proportion of the PTDtat fusion
protein remains trapped in non-cytosolic compartments
even though it is efficiently taken up by the cells. This
apparently would compromise the therapeutic effect of
the fusion protein. In our study, we examined the distri-
bution of Ad5.PTDtat particles in cells at various time
points (from 0.5 hour to 4 hours) following addition of
the viruses to the cells by immunofluorescent staining,
and found that the distribution of Ad5.PTDtat inside the
cells was similar to that of unmodified Ad5 vectors (data
not shown). This indicates endosomal trapping is not sig-
nificant, if any present at all, with Ad5.PTDtat infection of
cells. In addition, the enhanced gene delivery mediated by
Ad5.PTDtat confirmed that the virions were able to effi-
ciently escape the endosomal compartment.
The potential utility of the infectivity-enhanced Ad5.PTD-
tat vector in cancer gene therapy was initially investigated
in this study using low-CAR expressing tumor models.
Indeed, many tumor cells have been shown to express
very low levels of CAR, which is partially responsible for
the low efficacy of Ad5 mediated cancer gene therapy in in
vivo studies, especially in clinical trials [1-3]. The ability of
Ad5.PTDtat to improve the gene delivery efficacy is attrib-
utable to the PTDtat motif, which binds to the negatively
charged motifs expressed on cell surface, in particular,
heparan sulfate containing proteoglycans that are widely
expressed in a variety of cells including tumor cells [49-
51]. In addition to cancer gene therapy, Ad5.PTDtat may
also be applied in other gene therapy applications where
infectivity-enhancement is beneficial. Infectivity-
enhanced vectors will not only allow efficient gene deliv-
ery into low-CAR target cells, but also allow use of a
reduced amount of viral vectors, thus reducing vector-
associated toxicity.
Previous studies have developed several other infectivity-
enhanced vectors, which include Ad5 vectors modified
with RGD, polylysine, or knobs from other Ad serotypes
[13-15,52]. Since each of the modified vectors uses a
unique extra targeting motif, the enhanced gene delivery
efficacy in a specific cell type depends on the expression of
individual receptors on its cell surface. Similar to PTDtat,
the polylysine epitope, which is composed of a stretch of
lysine residues, is highly basic, and can utilize heparan
sulfate as its receptor. Nonetheless, the interaction
between PTDtat and heparan sulfate is not only based on
ionic intereactions, but also on the specific structures of
the peptide and the proteoglycans [27-29]. Therefore, the
choice of an infectivity-enhanced vector needs to be deter-
mined for each specific application involving gene deliv-
ery enhancement.
Conclusion
Our data showed that a genetically modified Ad5 vector,
Ad5.PTDtat, maintained the ability to interact with its
native receptor CAR, and delivered transgenes into both
high-CAR and low-CAR cells more efficiently than the
unmodified Ad5 vector. Our data further showed
Ad5.PTDtat infected cells via both CAR and PTDtat path-
ways. More significantly, Ad5.PTDtat exhibited enhanced
gene delivery in vivo in a tumor model, and thus may be
useful for gene therapy applications involving low gene
delivery efficacy.
Methods
Cell culture
The human embryonic kidney 293 cells stably trans-
formed with Ad-E1 DNA, human lung carcinoma A549
cells, human cervix adenocarcinoma Hela cells, human
embryonic rhabdomyosarcoma RD cells, and human gli-Virology Journal 2007, 4:103 http://www.virologyj.com/content/4/1/103
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oma D65MG and U118MG cells were all obtained from
the American Type Culture Collection (ATCC, Manassas,
VA). The 293 cells, A549 cells and U118MG cells were cul-
tured in Dulbecco's modified Eagle's medium/Ham's F12
medium (DMEM/F12) containing 10% fetal bovine
serum (FBS) and 2 mM L-glutamine. Hela cells were cul-
tured cultured in minimum essential Eagle medium
(MEM) containing 10% FBS and 2 mM L-glutamine. Both
RD and D65MG cells were cultured in DMEM containing
10% FBS and 2 mM L-glutamine. All of the cells were
maintained at 37°C in a 5% CO2 humidified incubator.
Generation of the Ad5.PTDtat vector
Genetic modification of the Ad5 vector with PTDtat was
achieved using our previously established fiber modifica-
tion system [15]. In brief, the fiber shuttle vector contain-
ing a unique SnaBI restriction site immediately in front of
the stop code of the fiber gene, named pNEB.PK.SnaBI,
was used to generate a PTDtat modification. The sense and
antisense oligonucleotides encoding the PTDtat motif, 5'-
phos-ACT TTT TCA TAC ATT GCG CAA GAA GGC GGT
GGA GGG TAT GGC AGG AAG AAG CGG AGA CAG CGA
CGA AGA TAA TAA A-3' (sense) and 5'-phos-TTT ATT ATC
TTC GTC GCT GTC TCC GCT TCT TCC TGC CAT ACC
CTC CAC CGC CTT CTT GCG CAA TGT ATG AAA AAG T
-3' (antisense), were annealed and cloned into the fiber
shuttle vector pNEB.PK.SnaBI. This resulted in the fiber
modified shuttle vector pNEB.PK.PTDtat. In order to incor-
porate the modified fiber into an Ad5 genome,
pNEB.PK.PTDtat  was linearized and recombined in
Escherichia coli (E. coli) BJ5183 with a linearized Ad5 back-
bone plasamid pVK50 that contained the CMV promoter
driven GFP reporter gene in its E1 region. After the posi-
tive recombinant plasmid, designated pAd5.PTDtat, was
identified, stable and high quality plasmid was obtained
from E. coli DH5α after re-transformation of the construct.
The modification was confirmed by sequencing analysis.
The modified virus Ad5.PTDtat was rescued and purified as
previously described [53]. In brief, the pAd5.PTDtat plas-
mid was digested with PacI (to release the viral genome),
purified, and transfected into 293 cells stably expressing
the complementary E1 genes. After the virus plaques
formed, they were amplified in 293 cells, and purified uti-
lizing a standard CsCl gradient protocol. The viral particle
(VP) titer was determined using a conversion factor of 1.1
× 1012 VPs/ml per absorbance unit at 260 nm.
ELISA
The ELISA binding assay was performed essentially as
described [15]. In brief, 109 VPs of either Ad5 or Ad5.PTD-
tat in 100 µl of 100 mM carbonate buffer (pH 9.5) was
immobilized in each well of a 96-well maxisorp plate
(Nunc, Roskilde, Denmark) by overnight incubation at
4°C. Following extensive washes with Tris-buffered saline
(TBS) containing 0.05% Tween 20 (TBS-Tween), and
blocking with 2% bovine serum albumin (BSA) in TBS-
Tween, the viruses were incubated with varying amounts
of purified recombinant sCAR. The binding of sCAR to the
viruses was detected by incubation with anti-CAR anti-
body (Santa Cruz Biotechnology Inc., Santa Cruz, CA),
followed by an AP-conjugated secondary antibody incu-
bation. AP activity reflecting the amount of bound sCAR
was determined using a color reaction with p-nitrophenyl
phosphate (Sigma, St. Louis, MO) as recommended by
the manufacturer. The absorbance at 405 nm (OD405)
was obtained using PowerWaveHT 340 microplate reader
(BioTek Instruments Inc., Winooski, VT).
Cell binding assay
Cells were cultured in 6-well plates until they were conflu-
ent. The plate was then cooled down on ice, and incu-
bated with Ad5 or Ad5.PTDtat at an MOI of 5000 VPs/cell
for one hour at 4°C. After washing cells twice with cold
phosphate buffered saline (PBS) on ice, the cells were col-
lected by incubation with Versene (0.53 mM EDTA). After
two more washes with PBS, the cells were lysed and proc-
essed to isolate DNA (Qiagen Inc., Valencia, CA). The viral
copy number in the DNA samples were obtained by quan-
titative PCR using primers designed for the E4 region of
adenoviral genome. The data were normalized against
actin DNA in each sample.
Gene transfer assay
Gene transfer efficacy of the viral vectors was assessed with
the use of GFP reporter. In the assay, cells were plated in
24-well plates with a density of 105 cells per well the day
before infection. Then the cells were infected with Ad5 or
Ad5.PTDtat at MOIs of 100 or 500 VPs/cell as described
previously [53]. Two days later, GFP expression was exam-
ined by fluorescence microscopy and quantified by a Syn-
ergy HT fluorescence plate reader (BioTek Instruments
Inc., Winooski, VT).
Competitive inhibition assays
Low-CAR U118MG cells or high-CAR A549 cells were
plated in 24-well plates at a density of 105 cells per well
the day before infection. Viruses equivalent to an MOI of
100 VPs/cell were used for each infection. To block cell
surface CAR, recombinant knob protein was pre-incu-
bated with cells at a final concentration of 50 µg/ml prior
to viral infection [54], and to block the PTDtat epitope, the
viruses were pre-incubated with 100 µg/ml of heparin
[15,54]. Two hours after infection, the cells were washed
with PBS, and refreshed with complete media containing
10% FBS. The cells were cultured for two days in the
humidified 37°C, 5% CO2 incubator, and GFP micros-
copy was performed to examine the transgene expression.Virology Journal 2007, 4:103 http://www.virologyj.com/content/4/1/103
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In vivo gene delivery
The subcutaneous tumors were established in athymic
nude mice using 1 × 107 U118MG cells per tumor per
mouse. After the tumors developed to ~0.5 cm in diame-
ter, PBS or 1010 VPs of Ad5 or Ad.PTDtat were injected into
each tumor (n = 6). GFP expression was analyzed at 3, 7,
and 10 days post infection using a custom-built non-inva-
sive optical imaging system described previously [55]. The
mice were placed in the imaging chamber under anesthe-
sia with 3% isoflurane. Green fluorescence images were
acquired at f/8 with 20-second exposure using a combina-
tion of excitation filter HQ487/15× and emission filter
D535/30m (Chroma Technology, Rockingham, VT) sup-
ported by WinView32 software (Roper Scientific Inc.,
Trenton, NJ). All of the procedures involving animals
were approved by the Institutional Animal Care and Use
Committee of the University of Alabama at Birmingham
and performed according to their guidelines.
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